Phenacetin acts as a weak genotoxic compound preferentially in the kidney of DNA repair deficient Xpa mice

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 596, Issue 1-2 SPEC. ISS., 2006, Pages 143-150

  Luijten, Mirjam ^a   Speksnijder, Ewoud N ^a   van Alphen, Niels ^a   Westerman, Anja ^a   Heisterkamp, Siem H ^a   van Benthem, Jan ^a   van Kreijl, Coen F ^a   Beems, Rudolf B ^a   van Steeg, Harry ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

Author keywords

Analgesic; DNA repair deficient Xpa mice; Genotoxicity; Kidney; lacZ Reporter gene; Phenacetin

Indexed keywords

ANALGESIC AGENT; BETA GALACTOSIDASE; PHENACETIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DNA REPAIR; DRUG EXPOSURE; FEMALE; GENE DELETION; GENE FREQUENCY; GENE MUTATION; GENOTOXICITY; INDUCED MUTATION; KIDNEY; LIVER; MALE; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SEX DIFFERENCE; SEX RATIO; SPLEEN; STATISTICAL SIGNIFICANCE; WILD TYPE;

ANIMALS; CARCINOGENS; FEMALE; KIDNEY; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTAGENS; MUTATION; PHENACETIN; SEX CHARACTERISTICS; SPLEEN; TUMOR SUPPRESSOR PROTEIN P53; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ANIMALIA;

EID: 33645995140     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2005.12.011     Document Type: Article

References (48)

1. Hultengren N., Lagergren C., and Ljungqvist A. Carcinoma of the renal pelvis in renal papillary necrosis. Acta Chir. Scand. 130 (1965) 314-320
2. Bengtsson U., Angervall L., Ekman H., and Lehmann L. Transitional cell tumors of the renal pelvis in analgesic abusers. Scand. J. Urol. Nephrol. 2 (1968) 145-150
3. Mahony J.F., Storey B.G., Ibanez R.C., and Stewart J.H. Analgesic abuse, renal parenchymal disease and carcinoma of the kidney or ureter. Aust. N.Z. J. Med. 7 (1977) 463-469
4. Angervall L., Bengtsson U., Zetterlund C.G., and Zsigmond M. Renal pelvic carcinoma in a Swedish district with abuse of a phenacetin-containing drug. Br. J. Urol. 41 (1969) 401-405
5. Johansson S., Angervall L., Bengtsson U., and Wahlqvist L. Uroepithelial tumors of the renal pelvis associated with abuse of phenacetin-containing analgesics. Cancer 33 (1974) 743-753
6. Adam W.R., Dawborn J.K., Price C.G., Riddell J., and Story H. Anaplastic transitional-cell carcinoma of the renal pelvis in association with analgesic abuse. Med. J. Aust. 1 (1970) 1108-1109
7. Hoybye G., and Nielsen O.E. Renal pelvic carcinoma in phenacetin abusers. Scand. J. Urol. Nephrol. 5 (1971) 190-192
8. Liu T., Smith G.W., and Rankin J.T. Renal pelvic tumor associated with analgesic abuse. Can. Med. Assoc. J. 107 (1972) 768
9. McCredie M., Ford J.M., Taylor J.S., and Stewart J.H. Analgesics and cancer of the renal pelvis in New South Wales. Cancer 49 (1982) 2617-2625
10. McCredie M., Stewart J.H., Ford J.M., and MacLennan R.A. Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br. J. Urol. 55 (1983) 220-224
11. McCredie M., Stewart J.H., and Ford J.M. Analgesics and tobacco as risk factors for cancer of the ureter and renal pelvis. J. Urol. 130 (1983) 28-30
12. McLaughlin J.K., Blot W.J., Mehl E.S., and Fraumeni Jr. J.F. Relation of analgesic use to renal cancer: population-based findings. Natl. Cancer Inst. Monogr. 69 (1985) 217-222
13. McCredie M., Stewart J.H., Carter J.J., Turner J., and Mahony J.F. Phenacetin and papillary necrosis: independent risk factors for renal pelvic cancer. Kidney Int. 30 (1986) 81-84
14. McCredie M., and Stewart J.H. Does paracetamol cause urothelial cancer or renal papillary necrosis?. Nephron 49 (1988) 296-300
15. Jensen O.M., Knudsen J.B., Tomasson H., and Sorensen B.L. The Copenhagen case-control study of renal pelvis and ureter cancer: role of analgesics. Int. J. Cancer 44 (1989) 965-968
16. McCredie M., Stewart J.H., and Day N.E. Different roles for phenacetin and paracetamol in cancer of the kidney and renal pelvis. Int. J. Cancer 53 (1993) 245-249
17. IARC Monographs on the evaluation of the carcinogenic risks to humans: some pharmaceutical drugs, IARC Monographs 24, 1980, pp. 135-161.
18. IARC Monographs on the evaluation of the carcinogenic risks to humans: overall evaluations of carcinogenicity: an updating of IARC Monographs volumes 1 to 42, IARC Monographs Suppl. 7, 1987, pp. 310-312.
19. Johansson S.L. Carcinogenicity of analgesics: long-term treatment of Sprague-Dawley rats with phenacetin, phenazone, caffeine and paracetamol (acetamidophen). Int. J. Cancer 27 (1981) 521-529
20. Nakanishi K., Kurata Y., Oshima M., Fukushima S., and Ito N. Carcinogenicity of phenacetin: long-term feeding study in B6c3f1 mice. Int. J. Cancer 29 (1982) 439-444
21. De Flora S., Russo P., Pala M., Fassina G., Zunino A., Bennicelli C., Zanacchi P., Camoirano A., and Parodi S. Assay of phenacetin genotoxicity using in vitro and in vivo test systems. J. Toxicol. Environ. Health 16 (1985) 355-377
22. Oldham J.W., Preston R.F., and Paulson J.D. Mutagenicity testing of selected analgesics in Ames Salmonella strains. J. Appl. Toxicol. 6 (1986) 237-243
23. Robbiano L., Carrozzino R., Puglia C.P., Corbu C., and Brambilla G. Correlation between induction of DNA fragmentation and micronuclei formation in kidney cells from rats and humans and tissue-specific carcinogenic activity. Toxicol. Appl. Pharmacol. 161 (1999) 153-159
24. Stewart J.H., Hobbs J.B., and McCredie M.R. Morphologic evidence that analgesic-induced kidney pathology contributes to the progression of tumors of the renal pelvis. Cancer 86 (1999) 1576-1582
25. Bringuier P.P., McCredie M., Sauter G., Bilous M., Stewart J., Mihatsch M.J., Kleihues P., and Ohgaki H. Carcinomas of the renal pelvis associated with smoking and phenacetin abuse: p53 mutations and polymorphism of carcinogen-metabolizing enzymes. Int. J. Cancer 79 (1998) 531-536
26. de Vries A., van Oostrom C.T., Hofhuis F.M., Dortant P.M., Berg R.J., de Gruijl F.R., Wester P.W., van Kreijl C.F., Capel P.J., van Steeg H., and Verbeek S.J. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature 377 (1995) 169-173
27. de Vries A., Dollé M.E., Broekhof J.L., Muller J.J., Kroese E.D., van Kreijl C.F., Capel P.J., Vijg J., and van Steeg H. Induction of DNA adducts and mutations in spleen, liver and lung of XPA-deficient/lacZ transgenic mice after oral treatment with benzo[a]pyrene: correlation with tumor development. Carcinogenesis 18 (1997) 2327-2332
28. Ide F., Iida N., Nakatsuru Y., Oda H., Tanaka K., and Ishikawa T. Mice deficient in the nucleotide excision repair gene XPA have elevated sensitivity to benzo[a]pyrene induction of lung tumors. Carcinogenesis 21 (2000) 1263-1265
29. Hoogervorst E.M., de Vries A., Beems R.B., van Oostrom C.T., Wester P.W., Vos J.G., Bruins W., Roodbergen M., Cassee F.R., Vijg J., van Schooten F.J., and van Steeg H. Combined oral benzo[a]pyrene and inhalatory ozone exposure have no effect on lung tumor development in DNA repair-deficient Xpa mice. Carcinogenesis 24 (2003) 613-619
30. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T., and Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4 (1994) 1-7
31. +/- knockout mice: overview of available data. Toxicol. Pathol. 29 Suppl. (2001) 117-127
32. Lina B.A., Woutersen R.A., Bruijntjes J.P., van Benthem J., van den Berg J.A., Monbaliu J., Thoolen B.J., Beems R.B., and van Kreijl C.F. Evaluation of the Xpa-deficient transgenic mouse model for short-term carcinogenicity testing: 9-month studies with haloperidol, reserpine, phenacetin, and d-mannitol. Toxicol. Pathol. 32 (2004) 192-201
33. Boerrigter M.E., Dollé M.E., Martus H.J., Gossen J.A., and Vijg J. Plasmid-based transgenic mouse model for studying in vivo mutations. Nature 377 (1995) 657-659
34. Dollé M.E., Martus H.J., Gossen J.A., Boerrigter M.E., and Vijg J. Evaluation of a plasmid-based transgenic mouse model for detecting in vivo mutations. Mutagenesis 11 (1996) 111-118
35. Dollé M.E., Martus H.J., Novak M., van Orsouw N.J., and Vijg J. Characterization of color mutants in lacZ plasmid-based transgenic mice, as detected by positive selection. Mutagenesis 14 (1999) 287-293
36. Data Analysis Products Division. S-PLUS 2000 Guide to Statistics (1999), MathSoft, Seattle
37. Spiegelhalter D.J., Thomas A., Best N.G., and Gilks W.R. BUGS: Bayesian Inference Using Gibbs Sampling, Version 0.5 (1996), MRC Biostatistics Unit, Cambridge
38. Dollé M.E., Snyder W.K., Dunson D.B., and Vijg J. Mutational fingerprints of aging. Nucleic Acids Res. 30 (2002) 545-549
39. -/- mice. Carcinogenesis 22 (2001) 619-626
40. Nohmi T., Mizokami K., Kawano S., Fukuhara M., and Ishidate Jr. M. Metabolic activation of phenacetin and phenetidine by several forms of cytochrome P-450 purified from liver microsomes of rats and hamsters. Jpn. J. Cancer Res. 78 (1987) 153-161
41. Patierno S.R., Lehman N.L., Henderson B.E., and Landolph J.R. Study of the ability of phenacetin, acetaminophen, and aspirin to induce cytotoxicity, mutation, and morphological transformation in C3H/10T1/2 clone 8 mouse embryo cells. Cancer Res. 49 (1989) 1038-1044
42. Camus A.M., Friesen M., Croisy A., and Bartsch H. Species-specific activation of phenacetin into bacterial mutagens by hamster liver enzymes and identification of N-hydroxyphenacetin O-glucuronide as a promutagen in the urine. Cancer Res. 42 (1982) 3201-3208
43. Wirth P.J., Alewood P., Calder I., and Thorgeirsson S.S. Mutagenicity of N-hydroxy-2-acetylaminofluorene and N-hydroxyphenacetin and their respective deacetylated metabolites in nitroreductase deficient Salmonella TA98FR and TA100FR. Carcinogenesis 3 (1982) 167-170
44. Löfgren S., Hagbjörk A.L., Ekman S., Fransson-Steen R., and Terelius Y. Metabolism of human cytochrome P450 marker substrates in mouse: a strain and gender comparison. Xenobiotica 34 (2004) 811-834
45. Khan K.N., and Alden C.L. Kidney. In: Haschek W., Rousseaux C., and Wallig M.A. (Eds). Handbook of Toxicologic Pathology (2002), Academic Press, San Diego 255-336
46. van Oostrom C.T., Boeve M., van Den B.J., de Vries A., Dollé M.E., Beems R.B., van Kreijl C.F., Vijg J., and van Steeg H. Effect of heterozygous loss of p53 on benzo[a]pyrene-induced mutations and tumors in DNA repair-deficient XPA mice. Environ. Mol. Mutagen. 34 (1999) 124-130
47. Hoogervorst E.M., van Oostrom C.T., Beems R.B., van Benthem J., Gielis S., Vermeulen J.P., Wester P.W., Vos J.G., de Vries A., and van Steeg H. p53 heterozygosity results in an increased 2-acetylaminofluorene-induced urinary bladder but not liver tumor response in DNA repair-deficient Xpa mice. Cancer Res. 64 (2004) 5118-5126
48. Tannapfel A., Hahn H.A., Katalinic A., Fietkau R.J., Kuhn R., and Wittekind C.W. Incidence of apoptosis, cell proliferation and P53 expression in renal cell carcinomas. Anticancer Res. 17 (1997) 1155-1162